We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
News

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710
News

Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Update on Phase II/III Clinical Trial of Investigational Staphylococcus aureus Vaccine, V710"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Merck and Intercell AG have announced that following a pre‐specified interim analysis from the Phase II/III clinical trial evaluating V710, an investigational vaccine for the prevention of Staphylococcus aureus (S. aureus) infection, the independent Data Monitoring Committee (DMC) recommended suspension of enrollment.

Although the trial did not meet the pre‐specified futility criteria, the DMC nonetheless recommended suspension of enrollment pending further analyses of the benefit/risk profile of the vaccine candidate. Merck and Intercell plan to provide a further update when analyses have been completed.

Advertisement